Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
Bioinformatics (Oxford, England)|June 20, 2012
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion modelFrancesco Abate, Andrea Acquaviva, Giulia Paciello, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Plos One|May 24, 2016
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsVaclava Polivkova, Peter Rohon, Hana Klamova, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Hematological Oncology|January 29, 2020
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axisManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Cancer Medicine|March 11, 2020
Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paperSimona Soverini, Francesco Albano, Renato Bassan, et al.
Clinical Chemistry|September 23, 2003
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLCMichele Bianchini, Emanuela Ottaviani, Tiziana Grafone, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
Bioinformatics (Oxford, England)|June 20, 2012
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion modelFrancesco Abate, Andrea Acquaviva, Giulia Paciello, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Plos One|May 24, 2016
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsVaclava Polivkova, Peter Rohon, Hana Klamova, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Hematological Oncology|January 29, 2020
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axisManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Cancer Medicine|March 11, 2020
Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paperSimona Soverini, Francesco Albano, Renato Bassan, et al.
Clinical Chemistry|September 23, 2003
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLCMichele Bianchini, Emanuela Ottaviani, Tiziana Grafone, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Pageof 17